AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Alexander's, Inc.
Video analysis: ALX
All videosNo video analysis for this stock yet. Request one from our team.
News: ALX
Head-To-Head Analysis: Tritax Big Box REIT (OTCMKTS:TTBXF) vs. Alexander’s (NYSE:ALX)
Alexander's (NYSE: ALX - Get Free Report) and Tritax Big Box REIT (OTCMKTS:TTBXF - Get Free Report) are both real estate companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Earnings and Valuation This table compares
ALX Oncology to Present at Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
Is Alexander's (ALX) Outperforming Other Finance Stocks This Year?
Here is how Alexander's (ALX) and Healthpeak (DOC) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for August 11th
DINO, QUAD and ALX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 11, 2026.
New Strong Buy Stocks for August 11th
ALX, DINO, OPBK, CYD and HLLY have been added to the Zacks Rank #1 (Strong Buy) List on August 11, 2026.
Best Income Stocks to Buy for August 11th
ALX, SHIP and QUAD made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 11, 2026.
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept – – Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 – – Strengthened leadership team with the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Alexander's (ALX) Upgraded to Strong Buy: Here's Why
Alexander's (ALX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Similar companies
-
Chimera Investment Corporation
CIM
·
New York Stock Exchange
Compare
-
American Assets Trust, Inc.
AAT
·
New York Stock Exchange
Compare
-
Empire State Realty Trust, Inc.
ESRT
·
New York Stock Exchange
Compare
-
Orchid Island Capital, Inc.
ORC
·
New York Stock Exchange
Compare
-
Xenia Hotels & Resorts, Inc.
XHR
·
New York Stock Exchange
Compare
-
JBG SMITH Properties
JBGS
·
New York Stock Exchange
Compare